|
US2020069702A1
|
|
Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
|
|
WO2018058032A1
|
|
Antiestrogens and/or aromatase inhibitors for use in treating obesity and related symptoms
|
|
EP3402471A1
|
|
Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions
|
|
WO2017100324A1
|
|
Combination therapy for treating female hypoactive sexual desire disorders
|
|
WO2016106189A1
|
|
Cis-clomiphene and its analogues as agents for androgen deprivation therapy
|
|
WO2016089904A1
|
|
Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases
|
|
US2016038506A1
|
|
Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
|
|
CN106068121A
|
|
Single solvent is used to carry out clomiphene synthesis
|
|
AU2014275101A1
|
|
Trans-clomiphene and its analogues as agents that increase bone mineral density
|
|
MX2015004821A
|
|
Methods and compositions for treating progesterone-dependent conditions.
|
|
MX2015005160A
|
|
Trans-clomiphene for use in cancer therapy.
|
|
NZ704679A
|
|
Trans-clomiphene formulations and uses thereof
|
|
EP2819676A1
|
|
Combination therapy for treating androgen deficiency
|
|
CN104114162A
|
|
Selective estrogen receptor modulators with short half-lives and uses thereof
|
|
CA2841572A1
|
|
Trans-clomiphene metabolites and uses thereof
|
|
CN103403017A
|
|
Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
|
|
SG183924A1
|
|
Compositions and methods for non-toxic delivery of antiprogestins
|
|
TW201500041A
|
|
Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
|
|
TW201002330A
|
|
Compositions and methods for treating breast cancer
|
|
TW201002736A
|
|
Compositions and methods for treating progesterone-dependent conditions
|
